Lupin Limited announces it has received final approval from the U.S. Food and Drug Administration (FDA) for its pitolisant tablets. The company states the approval is for the product in the United States.
The Hindu also reports that Lupin has received an FDA nod for pitolisant tablets. While the outlets agree on the approval itself, they provide limited shared detail in the excerpts available, such as the specific indication, dosage strengths, or the timing of market launch. The PR Newswire release frames the news as a corporate milestone, while The Hindu relays the same regulatory outcome as a short report.
Overall, the coverage centers on the FDA’s decision and Lupin’s statement that the approval is final, indicating the company has met the FDA’s requirements for the tablet product. Additional particulars beyond the approval announcement are not included in the provided text from either source.
